Investors

As a global pharmaceutical company with a biotech mindset and a proven ability to provide new, life-changing therapies, Ipsen is a leading player in its core therapeutic areas.

Contact us

Craig Marks Nicolas Bogler
Vice President, Investor Relations Senior Manager, Investor Relations
+44 7584 349 193 +33 6  52 19 98 92

Contact us

Q1 2023 sales-update call

 

David Loew, Chief Executive Officer, is pleased to host a conference call and webcast to discuss Ipsen’s Q1 2023 sales performance on:

Date: Thursday, 27 April 2023

Time: Conference call and webcast – 2pm, Paris time

 

Participants can access the call and its details by registering

Register Here

Q1 2023 SALES-UPDATE CALL

Ipsen in Brief

Ipsen in Brief 2023

Discover Ipsen in two pages; our products and key figures, our objectives and our strategy.

Download

Registration document

2022 Universal Registration Document

The 2022 Universal registration document presents Ipsen’s activity, risk, financial information (objectives and forecasts), CSR, corporate governance and legal information of the Group.

Download

Research & Development pipeline

Ipsen R&D has a valuable pipeline encompassing both lifecycle management of our well-established products, and the development of innovative new molecules.

Learn more
© Ipsen Pharma, 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France. All rights reserved - 2023